a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi’s longer lasting version, Toujeo, and is likely to win a large share of the ...

Toujeo (insulin glargine injection) was approved in 2015 and is an injectable long-acting insulin. It is used for adults with type 1 or type 2 diabetes to improve glycemic control. It is ...

There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey announced a settlement agreement Tuesday with Sanofi-Aventis U.S. following ...

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...

Toujeo, which provides a steady insulin release over 24 hours via a once-daily injection, has become an essential solution for individuals with type 1 and type 2 diabetes. Its efficacy in ...